ArticleInvestigative ophthalmology & visual science2012
Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone.
Article in Investigative ophthalmology & visual science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02042027 (Subconjunctival IVIg), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Potential of Nanoparticle-Based Phototherapies for Future Treatment of Uveal Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Review
- Ocular Drug Delivery: Advancements and Innovations.Pharmaceutics · 2022Review
- An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization.International journal of nanomedicine · 2022Review
- Distribution of polymeric nanoparticles in the eye: implications in ocular disease therapy.Journal of nanobiotechnology · 2021Review
- Novel insights into gene therapy in the cornea.Experimental eye research · 2021Review
- Biomaterials for Modulating Lymphatic Function in Immunoengineering.ACS pharmacology & translational science · 2019Review
- Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review.Medicinal research reviews · 2018Review
- Corticosteroid-loaded biodegradable nanoparticles for prevention of corneal allograft rejection in rats.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- AAV2 delivery of Flt23k intraceptors inhibits murine choroidal neovascularization.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.Progress in retinal and eye research · 2013Review
- Corneal gene therapy: basic science and translational perspective.The ocular surface · 2013Review
- Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity.Blood · 2013Article
- BMP7 gene transfer via gold nanoparticles into stroma inhibits corneal fibrosis in vivo.PloS one · 2013Article
- Article
- Nanoparticles in the ocular drug delivery.International journal of ophthalmology · 2013Article
- Angiogenesis and lymphangiogenesis in corneal transplantation-A review.Survey of ophthalmologyReview
- Understanding lymphangiogenesis in knockout models, the cornea, and ocular diseases for the development of therapeutic interventions.Survey of ophthalmologyReview
- Nanotechnology approaches for ocular drug delivery.Middle East African journal of ophthalmologyReview
- Gene therapy in corneal transplantation.Seminars in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeTo determine if nanoparticles delivering plasmids expressing Flt23k (an anti-VEGF intraceptor) can enhance murine cornea transplant survival and whether their effect is synergistic with steroid therapy.
methodsBiodegradable PLGA Flt23k loaded or blank nanoparticles were prepared using the emulsion solvent evaporation
methodGraft survival, corneal neovascularization, and corneal lymphangiogenesis were compared among the Flt23k nanoparticles, blank nanoparticles, triamcinolone acetonide, and PBS groups following subconjunctival injection in mice that underwent penetrating keratoplasty. Graft survival, corneal neovascularization, and corneal lymphangiogenesis in a group treated with both nanoparticles and steroid therapy were also analyzed.
resultsThe Flt23k nanoparticle group showed less neovascularization, lymphangiogenesis, and graft failure compared with the PBS control group (P < 0.01). The 2-month graft survival rate was 20% in the Flt23k nanoparticle group with no grafts surviving in the PBS group. When the Flt23k nanoparticle was combined with steroid therapy, a significant increase in graft survival was seen compared with both steroid treatment alone (P < 0.05) and steroid combined with blank nanoparticle treatment (P < 0.05). The 2-month graft survival rate was 91.6% in the combination group compared with 47.6% in the triamcinolone-only group and 42.4% in the triamcinolone plus blank nanoparticle group.
conclusionsAnti-VEGF nanoparticles (Flt23k) have a significant effect on decreasing neovascularization and lymphangiogenesis, resulting in increased graft survival in penetrating keratoplasty. This beneficial effect is synergistically enhanced with steroid treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.